Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival

Abstract

Inactivation of the FANC–BRCA pathway via promoter methylation of the FANCF gene renders cells sensitive to DNA crosslinking agents, and has been identified in ovarian cancer cell lines and sporadic primary tumor tissues. We investigated epigenetic alterations in the FANC–BRCA pathway in head and neck squamous cell carcinomas (HNSCC) and non-small-cell lung cancers (NSCLC) using methylation-specific PCR. Promoter methylation of FANCF occurred in 15% (13/89) of HNSCCs and 14% (22/158) of NSCLCs. Methylation of BRCA1 occurred only in 6/158 NSCLC, and was limited to adenocarcinomas and large-cell carcinomas of the lung. No methylation of BRCA2 was detected. FANCF methylation was associated with a shorter duration of tobacco use (P=0.03) and a younger age of starting smoking (P=0.06) in NSCLC, and with a greater number of years of alcohol drinking (P=0.02) in HNSCC. In adenocarcinomas of the lung, FANCF promoter methylation was a significant predictor of poor survival with a hazard ratio of 3.1 (95% CI 1.2–7.9). This study demonstrates that inactivation of the FANC–BRCA pathway is relatively common in solid tumors and may be related to tobacco and alcohol exposure and survival of these patients.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Alter BP . (1996). Am. J. Hematol., 53, 99–110.

  • Auerbach AD and Wolman SR . (1976). Nature, 261, 494–496.

  • Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S and Karlan BY . (2000). Cancer Res., 60, 5329–5333.

  • D'Andrea AD and Grompe M . (2003). Nat. Rev. Cancer, 3, 23–34.

  • Ehrlich M . (2002). Oncogene, 21, 5400–5413.

  • Esteller M, Corn PG, Baylin SB and Herman JG . (2001). Cancer Res., 61, 3225–3229.

  • Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB and Herman JG . (2000). J. Natl. Cancer Inst., 92, 564–569.

  • Fang JY and Xiao SD . (2001). J. Gastroenterol. Hepatol., 16, 960–968.

  • Gras E, Cortes J, Diez O, Alonso C, Matias-Guiu X, Baiget M and Prat J . (2001). Cancer, 92, 787–795.

  • Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M and Kelsey KT . (2002). Oncogene, 21, 4231–4236.

  • Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.

  • Ishida R and Buchwald M . (1982). Cancer Res., 42, 4000–4006.

  • Joenje H and Patel KJ . (2001). Nat. Rev. Genet., 2, 446–457.

  • Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ and Kelsey KT . (2001a). Oncogene, 20, 1765–1770.

  • Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, Mark EJ and Kelsey KT . (2001b). Cancer Res., 61, 3419–3424.

  • Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro P, Hanenberg H and Auerbach AD . (2003). Blood, 101, 1249–1256.

  • Miyamoto K, Fukutomi T, Asada K, Wakazono K, Tsuda H, Asahara T, Sugimura T and Ushijima T . (2002). Jpn. J. Clin. Oncol., 32, 79–84.

  • Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC and Kelsey KT . (1999). J. Natl. Cancer Inst., 91, 2032–2038.

  • Olshan AF, Weissler MC, Pei H, Conway K, Anderson S, Fried DB and Yarbrough WG . (1997). Oncogene, 14, 811–818.

  • Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn Jr PA, Carney D, Minna JD and Mulshine JL . (1996). J. Cell Biochem. Suppl., 24, 32–91.

  • Potter JD . (1999). J. Natl. Cancer Inst., 91, 916–932.

  • Rice JC, Ozcelik H, Maxeiner P, Andrulis I and Futscher BW . (2000). Carcinogenesis, 21, 1761–1765.

  • Rothman K and Keller A . (1972). J. Chronic Dis., 25, 711–716.

  • Sasaki MS and Tonomura A . (1973). Cancer Res., 33, 1829–1836.

  • Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC and D'Andrea AD . (2003). Nat. Med., 9, 568–574.

  • Wang X, Christiani DC, Wiencke JK, Fischbein M, Xu X, Cheng TJ, Mark E, Wain JC and Kelsey KT . (1995). Cancer Epidemiol. Biomarkers Prev., 4, 543–548.

Download references

Acknowledgements

We thank E Ringstrom and E Peters for help with the HNSCC data collection. This work was supported by NIH grants ES00002, CA78609, and T32CA09078 (CJM).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karl T Kelsey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marsit, C., Liu, M., Nelson, H. et al. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23, 1000–1004 (2004). https://doi.org/10.1038/sj.onc.1207256

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207256

Keywords

This article is cited by

Search

Quick links